ShankerValleau Wealth Advisors Inc. Makes New Investment in AbbVie Inc. $ABBV

ShankerValleau Wealth Advisors Inc. acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,088 shares of the company’s stock, valued at approximately $546,000. AbbVie comprises approximately 0.1% of ShankerValleau Wealth Advisors Inc.’s investment portfolio, making the stock its 23rd biggest position.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Burk Holdings LLC bought a new position in AbbVie during the second quarter worth about $30,000. Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie during the 1st quarter worth about $34,000. Marquette Asset Management LLC grew its position in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. IMG Wealth Management Inc. increased its stake in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after acquiring an additional 153 shares during the last quarter. Finally, Principia Wealth Advisory LLC increased its stake in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of analyst reports. Oppenheimer increased their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. HSBC boosted their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Morgan Stanley boosted their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, BMO Capital Markets increased their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie Trading Up 0.7%

ABBV stock opened at $285.32 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The firm has a market cap of $504.10 billion, a PE ratio of 80.60, a P/E/G ratio of 1.30 and a beta of 0.24. The business’s 50-day moving average price is $262.74 and its two-hundred day moving average price is $239.22.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s payout ratio is currently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.